#USA #Ibezapolstat #Acurx #Staten Island #CDI

Acurx Pharmaceuticals Announces Key Findings from Novel Study

Acurx Pharmaceuticals, a biopharmaceutical company focused on developing innovative treatments for challenging bacterial infections, recently unveiled significant findings about their lead antibiotic candidate, Ibezapolstat (IBZ). This groundbreaking study represents the first direct comparison among the gut microbiome impacts of Ibezapolstat and other antibiotics used against Clostridioides difficile Infection (CDI), including vancomycin, metronidazole, and fidaxomicin, in a germ-free mouse model. Published in the Journal of Antimicrobial Agents and Chemotherapy, the study highlights how Ibezapolstat initiates less disruption to the gut microbiome when compared to other commonly prescribed antibiotics.

The research indicates that the impact IBZ has on the gut microbiome is distinctly different from its counterparts. Following treatment with Ibezapolstat, changes to the alpha and beta microbiome diversities were significantly less pronounced than those observed in groups treated with vancomycin and metronidazole, suggesting a more selective antibacterial action. Notably, the study found a marked difference between the microbiome configurations for Ibezapolstat and fidaxomicin, which could potentially help distinguish these two antibiotics in future therapies.

Dr. Kevin Garey, a co-author of the study and a prominent microbiology researcher, stated, "This work is essential in understanding how Ibezapolstat operates. The distinct effects it has on the microbiome alongside its selective action compared to broader-spectrum antibiotics opens avenues for better management of CDI."

These findings could provide a competitive advantage for Acurx as it prepares to advance Ibezapolstat into international Phase 3 clinical trials for treating CDI. The potential for Ibezapolstat to minimize microbiome disruption aligns with the increasing need for novel antibiotics that mitigate the risk of recurrent CDI occurrences, a common and debilitating consequence of existing treatment options.

In the study, the gut microbiome changes induced by Ibezapolstat were significantly lower, marking a more favorable profile in how it interacts with beneficial gut bacteria. By preserving important bacterial phyla while treating CDI, Ibezapolstat may help mitigate the risk of future infections. Previous data indicate an uptick in beneficial Actinobacteria among those treated with Ibezapolstat, a factor that could thwart C. difficile growth and maintain microbiome balance.

Acurx’s clinical studies have also shown promising results, with a 96% Clinical Cure rate observed during Phase 2 trials. Patients treated with Ibezapolstat reported a significant reduction in recurrence rates, a common issue faced by those treated with other antibiotics.

Acurx’s Executive Chairman, Bob DeLuccia, commented on the results, "This pioneering comparative analysis not only establishes Ibezapolstat's unique standing among anti-CDI antibiotics but also solidifies the groundwork for forthcoming clinical studies. Our aim is to ensure that Ibezapolstat not only treats infections but also supports patient recovery by maintaining a healthy microbiome."

With regulatory guidance received from the European Medicines Agency (EMA), Acurx feels prepared to move forward with international Phase 3 trials, a significant step in the journey toward securing marketing authorization. If successful, Ibezapolstat could revolutionize CDI treatment by offering a targeted approach with a minimized impact on the gut microbiome, disproportionate to that of existing therapies.

Conclusion

In essence, Acurx Pharmaceuticals is paving the way for innovations in antibiotic development. The unique properties of Ibezapolstat could signify a new era in treating CDI, prioritizing microbiome health while combating infection. As the field of medication continues to evolve, Acurx stands at the forefront, ready to contribute significantly to health care’s ongoing battle against bacterial infections.

For further details on Acurx Pharmaceuticals and their pioneering work, please visit www.acurxpharma.com.